TNF and inflammatory bowel disease: A recent expert consensus statement on TDM of biologics in IBD by Cheifetz et al. supports the clinical utility of TDM during the induction phase for patients treated with anti-TNF agents, aiming at infliximab trough levels of 20–25 μg/ml at week 2 and 15–20 μg/ml at week 6, and adalimumab trough levels of 8–12 μg/ml at week 4 (12).